

Susan E. Barrowcliffe - Biography

















































































Log in






E-mail



Password







Remember




Forgot password ?









Become a member for free
Sign up





Sign up




New memberSign up for FREE


New customerDiscover our portfolios












 United States
 United Kingdom
 France
 Deutschland
 Schweiz (DE)
 Suisse (FR)










Settings

            Dynamic quotes 


OFFON

















Markets
Equities
North AmericaEuropeAsiaOceaniaMiddle East� More Equities

Indexes
DOW JONESS&P 500NASDAQ 100TSX COMPFTSE 100� More Indexes

Currency / Forex
EUR / USDGBP / USDUSD / JPYUSD / CADAUD / USD� More Currencies

Commodities
GOLDCrude Oil (WTI)Crude Oil (BRENT)SILVERPLATINUM� More Commodities


 News
Latest News
CompaniesMarketsEconomyCurrency / ForexCommoditiesInterest RatesBusiness LeadersFinancial calendarEconomic calendar

Listed company
Analyst reco.RumorsIPOsCapital Markets TransactionsNew ContractsProfits warningsAppointmentsPress ReleasesEventsCorporate actions

Sector News
EnergyBasic MaterialsIndustrialsConsumer CyclicalConsumer Non-CyclicalFinancialsHealthcareTechnologyTelecommunications ServicesUtilities


 Analysis
All AnalysisCommentariesIndex AnalysisStock Trading StrategiesCommodity AnalysisForex Analysis

 Stock Picks
All stock picks

 Portfolios
My Portfolio
Virtual portfolios
4-Traders Portfolios
European PortfolioUSA PortfolioAsian Portfolio


 Screeners
Market Screener HomeFundamental Analyse
Top Investor RatingTop Trading RatingTop ConsensusGrowth stocksYield stocksLow valuations

Technical Analysis
Oversold stocksOverbought stocksClose to resistancesClose to supportsAccumulation phaseMost volatile stocks


 Watchlists
My Watchlists
Watchlists
Top Lists
Yield stocksGrowth stocksUndervalued Stocks


 Top / Flop
Top News
Most Read NewsHot News

Top Fundamentals
Top CapitalizationTop YieldTop PERTop ConsensusTop Fundamentals

Top Technicals
Top RSIUnusual volumesTop GapsTop STIM

Top Movers
Top USATop CanadaTop U.K.Top GermanyTop EuropeTop Asia


 Tools
Market ScreenerDynamic chartFinancial calendarEconomic calendarSector researchCurrency converter

 Our Services
Premium AccessDiscover our Services

 



















 






4-Traders Homepage  >  News  >  Business Leaders  >  Business Leaders Biography


Business Leaders




Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors HomeAll newsMost read newsBusiness Leaders Biography


 
















Susan E. Barrowcliffe

Age : 59Linked companies :  Aimmune Therapeutics Inc 





Summary 



Ms. Susan E. Barrowcliffe is General Manager-Europe & Senior Vice President at Aimmune Therapeutics, Inc. Ms. Barrowcliffe was previously employed as Director-Regulatory & Medical Strategy by Idis Ltd., Vice President-Regulatory Affairs by Chiron Corp., Vice President-Regulatory Affairs by CHIRON Biopharmaceuticals, Vice President-Global Product Registration by Smithkline Beecham Plc, Director-European Regulatory Affairs by Marion Merrell Dow, Inc.,  by British Biotech Plc, Head-Regulatory Affairs by APT Pharmaceuticals, Inc., and Chief Executive Officer by Pharminox Ltd.She also served on the board at Right Track Regulatory Ltd.She received her undergraduate degree from The University of Sheffield.



Current positions of Susan E. Barrowcliffe 









 NameTitle
Since
 Aimmune Therapeutics Inc(Pharmaceuticals)
General Manager-Europe & Senior Vice President
-



Susan E. Barrowcliffe: Personal Network 







 NameLinked companies

Jeffrey H. Knapp Aimmune Therapeutics Inc 

Stephen George Dilly Aimmune Therapeutics Inc 

Kenneth F. Boehm Aimmune Therapeutics Inc 

Mark D. McDade Aimmune Therapeutics Inc 

Kathryn E. Falberg Aimmune Therapeutics Inc 

Patrick G. Enright Aimmune Therapeutics Inc 

Eric H. Bjerkholt Aimmune Therapeutics Inc 

Daniel C. Adelman Aimmune Therapeutics Inc 

Douglas T. Sheehy Aimmune Therapeutics Inc 

Mark T. Iwicki Aimmune Therapeutics Inc 




Most Read News 




07/19 JAMIE DIMON : JPMorgan's Jamie Dimon lashes out against Washington politics



07/19 DAVID HENRY : JPMorgan posts higher profit; shares dip on net interest income view



07/19DJJAMES MURDOCH : Top Energy News of the Day



07/19 RUPERT MURDOCH : Murdochs warn UK a delay to Sky-Fox deal could hit inward investment



07/19 PHILIP GREEN : Philip Green poaches Burberry man to be TopShop CEO



07/20 THOMAS WILSON : Most Japanese companies look to raise retirement age - Reuters poll



07/20 RUPERT MURDOCH : Murdoch made to wait few more weeks for Britain's Fox-Sky decision



07/21DJMUKESH AMBANI : Reliance's Ambani Launches Low-Cost Mobile Phone for India



07/21DJINDRA NOOYI : PepsiCo 'Stretches' Managers At Top -- WSJ



07/20DJSOREN SCHRODER : Top Stories of the Day



More news

 


            © 2017 People and Ownership :    









Advertisement








Susan E. Barrowcliffe : Connections 



 Sangamo Therapeutics Inc









Stephen George Dilly




 CardioDx Inc









Patrick G. Enright




 Dermira Inc









Mark D. McDade




 Merus NV









Mark T. Iwicki




 Urogen Pharma Ltd









Kathryn E. Falberg




 Trade Desk Inc









Kathryn E. Falberg




 Five Prime Therapeutics Inc









Mark D. McDade




 Axovant Sciences Ltd









Kathryn E. Falberg




 Pulmatrix Inc









Mark T. Iwicki




 Jazz Pharmaceuticals PLC









Patrick G. Enright




 Kala Pharmaceuticals Inc









Mark T. Iwicki




 Corium International Inc









Eric H. Bjerkholt




 Aimmune Therapeutics Inc









Jeffrey H. KnappStephen George DillyKenneth F. BoehmMark D. McDadeKathryn E. FalbergPatrick G. EnrightEric H. BjerkholtDaniel C. AdelmanDouglas T. SheehyMark T. Iwicki




Aptinyx, Inc.
                                            








Patrick G. Enright





American Association for Cancer Research
                                            








Daniel C. Adelman





ESS Technology, Inc.
                                            








Kathryn E. Falberg





Round Table Pizza, Inc.
                                            








Eric H. Bjerkholt





Longitude Capital Management Co. LLC
                                            








Patrick G. Enright





Pulmatrix Operating Co., Inc.
                                            








Mark T. Iwicki





UCB Pharma SA (Belgium)
                                            








Mark D. McDade





 







Popular Business Leaders 


 

Bernard Arnault
Mary Barra
Lloyd Blankfein
Michael Bloomberg
Yannick Bollor�
Warren Buffett
Jean-paul Clozel
Gary Cohn
Marc De Lacharri�re
Jamie Dimon
Ralph Dommermuth
Sebastian Ebel
John Edwards
David Einhorn
Jeff Fettig
Mark Fields
Carlos Ghosn
Terry Gou
David Henry
Carl Icahn
Michel Landel
Robin Li
Daniel Loeb
Maurice L�vy
Jack Ma
Marissa Mayer
Lakshmi Mittal
Rupert Murdoch
Elon Musk
Peter Nicholas
John Paulson
Nelson Peltz
Georges Plassat
Hasso Plattner
Thomas Rabe
Giuseppe Recchi
Wolfgang Reitzle
Wilbur Ross
Charles Schwab
Igor Sechin
Pascal Soriot
George Soros
Rupert Stadler
Bernard Tapie
Patrick Thomas
John Williamson
Thomas Wilson
Dieter Zetsche
Mark Zuckerberg



A-Z Business Leaders




 



























4-traders.com :MarketsNewsAnalysisStock PicksPortfoliosScreenersWatchlistsTop / FlopToolsOur ServicesAbout :Surperformance SASContact usAdvertiseLegal informationsAbout usStay Connected :FacebookTwitterPartners :B�rse: Aktien, Kurse und NachrichtenBest tweets 




   Copyright � 2017 Surperformance. All rights reserved.  












 














Slave
















 





AIMT Susan E. Barrowcliffe Insider Trades for Aimmune Therapeutics Inc.


































Bulletin






Investor Alert







New York Markets After Hours



Market Snapshot
Winners and Losers


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Aimmune Therapeutics Inc.

                  NASDAQ: AIMT
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Aimmune Therapeutics Inc.



After Hours
 --Quotes are delayed by 20 min
Jul 26, 2017, 4:39 p.m.


AIMT

/quotes/zigman/54531519/composite


$
21.93




Change

0.00
0.00%

Volume
Volume 58,696
Quotes are delayed by 20 min








/quotes/zigman/54531519/composite
Today's close

$
			21.65
		


$
				21.93
			
Change

+0.28
+1.29%





Day low
Day high
$21.13
$21.93










52 week low
52 week high

            $11.66
        

            $27.31
        


















Insider Activity


Individual




Susan E. Barrowcliffe



Ms. Susan E. Barrowcliffe is General Manager-Europe & Senior Vice President at Aimmune Therapeutics, Inc. and Head-Regulatory Affairs at APT Pharmaceuticals, Inc. Ms. Barrowcliffe was previously employed as Vice President-Regulatory Affairs by Chiron Corp., Chief Executive Officer by Pharminox Ltd, Vice President-Global Product Registration by Smithkline Beecham Plc, and Director-Drug Development by Vernalis Plc. She received her undergraduate degree from The University of Sheffield.



Transactions


Date
Shares
Transaction
Value





07/03/2017
15,000


 
Disposition at $20.26 per share.


303,900


07/03/2017
15,000


 
Derivative/Non-derivative trans. at $3.02 per share.


45,300


11/11/2016
20,000


 
Disposition at $25 per share.


500,000


11/11/2016
20,000


 
Derivative/Non-derivative trans. at $3.02 per share.


60,400


11/08/2016
15,000


 
Disposition at $20 per share.


300,000


11/08/2016
15,000


 
Derivative/Non-derivative trans. at $3.02 per share.


45,300





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Dr. Stephen George Dilly 
President, Chief Executive Officer & Director




Mr. Jeffrey H. Knapp 
Chief Operating Officer




Mr. Eric H. Bjerkholt 
Chief Financial Officer




Ms. Annette  Marcantonio 
Vice President-Clinical Operations




Dr. Daniel C. Adelman 
Chief Medical Officer




Dr. Mary M. Rozenman 
Senior VP-Corporate Development & Strategy




Ms. Susan E. Barrowcliffe 
General Manager-Europe & Senior Vice President




Ms. Le-Van  Nguyen 
Vice President-US Regulatory Affairs




Mr. Gregory  Behar 
Director




Dr. Laura G. Hansen 
Vice President-Investor Relations




Mr. Kenneth F. Boehm 
Vice President-Human Resources




Mr. Douglas T. Sheehy 
Secretary & General Counsel




Mr. William  Turner 
SVP-Global Regulatory Affairs & Quality Assurance




Mr. Mark D. McDade 
Chairman




Mr. Mark T. Iwicki 
Independent Director




Ms. Kathryn E. Falberg 
Independent Director




Ms. Stacey Denenberg Seltzer 
Independent Director




Mr. Patrick G. Enright 
Independent Non-Employee Director
















Log In




5:43 PM EDT
July 26, 2017


/marketstate/country/us
New York

	After


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
5:40pFacebook hits 2 billion users, earnings beat: Live blog
5:33pStock market ends at record on robust earnings as Fed issues policy update 
5:31pTrump puts his hands together for ‘the late, great Abraham Lincoln’
5:28pThe Nintendo Switch’s sell-out launch, in many charts
5:23p2-year Treasury yield falls the most in five weeks after Fed statement
5:20pFor transgender Americans, workplace discrimination isn’t limited to the military
5:09pYour 401(k) match may have some strings attached
5:07pThis is the worst mistake people make at work
5:06pWhy equal-weighted stock-market indexes bounce back faster from bear markets
5:05pNutrisystem shares rally on better-than-expected earnings
5:04pBuffalo Wild Wings drop 9% on 'high' chicken wing costs
5:04pBREAKINGF5 Networks shares fall after weak outlook, revenue miss
5:02pDonald Trump is winning the currency cold war: Pimco
5:01pHow to thrive at work when your boss wants you to quit
5:00pFacebook hits 2 billion users, earnings beat: Live blog
4:58p‘Game of Thrones’ science: Let’s take a closer look at that greyscale
4:56p‘Game of Thrones’: The four biggest takeaways from 'Stormborn’
4:48pBREAKINGNutrisystem shares jump 6.4% following Q2 earnings    
4:44pTop 10 most annoying people you may want to unfriend on Facebook 
4:43pIf you can buy only one stock or ETF, make it this one
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,711.01

+97.58
+0.45%





nasdaq

/quotes/zigman/12633936/realtime
6,422.75

+10.57
+0.16%





s&p 500

/quotes/zigman/3870025/realtime
2,477.83

+0.70
+0.03%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15





























































Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Insider Susan E. Barrowcliffe Sells 15,000 Shares | Daily Political











































































Home
About/Contact
Columnists
Privacy Policy
























Headlines
Politics
Nation
World
Issues
Economy
Finance




















Aimmune Therapeutics Inc. - Get News & Ratings Daily

		Enter your email address below to get the latest news and analysts' ratings for Aimmune Therapeutics Inc. with our FREE daily email newsletter:



 






Follow DailyPolitical

 
 










Latest News



Stericycle (SRCL) & Vertex Energy (VTNR) Financial Review					

Critical Contrast: Plains All American Pipeline, L.P. (NYSE:PAA) vs. Tallgrass Energy GP, (TEGP)					

Rent-A-Center Inc. (RCII) Issues  Earnings Results, Misses Expectations By $0.09 EPS					

J.B. Hunt Transport Services, Inc. (JBHT) Cut to “Sell” at BidaskClub					

Microchip Technology Incorporated (NASDAQ:MCHP) Downgraded by BidaskClub to Buy					

Energen Corporation (NYSE:EGN) Receives $67.05 Consensus PT from Analysts					

Lions Gate Entertainment Co. Class A Voting Shares (NASDAQ:LGF.A) Receives Average Recommendation of “Buy” from Analysts					

National Grid Transco, PLC (NGG) and PPL Corporation (NYSE:PPL) Head to Head Comparison					

Contrasting Cosi (COSI) and RCI Hospitality Holdings (RICK)					

Kornit Digital Ltd. (KRNT) Lowered to Buy at BidaskClub					

Western Gas Equity Partners, LP (WGP) Announces  Earnings Results, Beats Expectations By $0.07 EPS					

Head to Head Survey: TerraVia Holdings (NASDAQ:TVIA) and Platform Specialty Products Corporation (PAH)					

Gilead Sciences, Inc. (GILD) Declares Quarterly Dividend of $0.52					

Knight Transportation, Inc. (KNX) Announces Quarterly  Earnings Results					

Regal Beloit Corporation (NYSE:RBC) Announces Quarterly Dividend of $0.26					

Comparing SJW Corporation (SJW) & Middlesex Water (NASDAQ:MSEX)					

Xilinx, Inc. (XLNX) Releases Q2 Earnings Guidance					

Brokerages Set Medical Properties Trust, Inc. (NYSE:MPW) Target Price at $14.00					

Dream Global REIT to Issue Monthly Dividend of $0.07 (DRG.UN)					

Sprint Corporation (NYSE:S) Receives Consensus Rating of “Hold” from Analysts					





 





						Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Insider Susan E. Barrowcliffe Sells 15,000 Shares					

						 July 7th, 2017  - 0 comments - Filed Under -
 by Stacy Sanders 


							Filed Under: Finance - Insider Trades 







Tweet










Aimmune Therapeutics, Inc. (NASDAQ:AIMT) insider Susan E. Barrowcliffe sold 15,000 shares of the company’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $20.26, for a total value of $303,900.00. Following the completion of the transaction, the insider now directly owns 15,000 shares of the company’s stock, valued at approximately $303,900. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 
Shares of Aimmune Therapeutics, Inc. (AIMT) traded up 0.14% during trading on Friday, reaching $20.77. The company’s stock had a trading volume of 142,971 shares. Aimmune Therapeutics, Inc. has a 12-month low of $9.77 and a 12-month high of $27.31. The stock’s market cap is $1.05 billion. The stock’s 50-day moving average is $18.53 and its 200-day moving average is $19.95. 
Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings results on Monday, May 8th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.57) by $0.05.  Equities research analysts anticipate that  Aimmune Therapeutics, Inc. will post ($2.66) earnings per share for the current fiscal year. 




WARNING: “Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Insider Susan E. Barrowcliffe Sells 15,000 Shares” was originally  published by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.dailypolitical.com/2017/07/07/aimmune-therapeutics-inc-nasdaqaimt-insider-susan-e-barrowcliffe-sells-15000-shares.html. 
A number of brokerages have issued reports on AIMT. Zacks Investment Research cut Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, March 20th. ValuEngine raised Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 13th. Finally, Piper Jaffray Companies upped their target price on Aimmune Therapeutics to $40.00 and gave the stock an “overweight” rating in a report on Saturday, March 11th. One research analyst  has rated the stock with a hold rating and five have assigned  a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $33.00.
A number of large investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its position in  Aimmune Therapeutics by 454.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,979 shares of the biotechnology company’s stock valued at $130,000 after buying an additional 4,900 shares in the last quarter.  Daiwa SB Investments Ltd. bought a new position in  Aimmune Therapeutics during the first quarter valued at approximately $132,000.  American International Group Inc. increased its position in  Aimmune Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock valued at $352,000 after buying an additional 1,070 shares in the last quarter.  Nationwide Fund Advisors increased its position in  Aimmune Therapeutics by 23.7% in the first quarter. Nationwide Fund Advisors now owns 20,095 shares of the biotechnology company’s stock valued at $437,000 after buying an additional 3,851 shares in the last quarter.  Finally, Franklin Street Advisors Inc. NC bought a new position in  Aimmune Therapeutics during the first quarter valued at approximately $450,000. 69.64% of the stock is owned by hedge funds and other institutional investors. 
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.






Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



 
















 Comment on this Post

Click here to cancel reply.



Name (required)

Mail (will not be published) (required)

Website






Wordpress Hashcash needs javascript to work, but your browser has javascript disabled. Your comment will be placed in moderation!




Latest News




Jeff Sessions Spoke of Resigning After Tensions Increase with Trump





President Trump’s Tweets Complicate Already Complicated Week





World Leaders Very Critical of Paris Agreement Decision by Trump





Aide to President Trump Resigns With More Expected





Scud-Class Missile Launched by North Korea














			© DailyPolitical, LLC 2009-2017. All rights reserved. 


Privacy Policy |
			About | Columnists 
			| Contact 


































































Barrowcliffe Susan E. - Insider Stock Trading - OpenInsider











Sector

All Sectors

Group by Sector


Aerospace
Agriculture
Automobile
Building
Business Services
Chemical
Electrical
Energy
Fashion
Financial
Food & Beverage
Fund
Healthcare
Household
Insurance
Machinery
Media
Metals
Mining
Other
Personal Services
Real Estate
Retail
Technology
Telecom
Transportation
Utility




Industry

All Industries

Group by Industry






Insiders
Filings


All
Purchases
Sales

CIK: 1664251 - Address: Aimmune Therapeutics, Inc., 8000 Marina Boulevard, Suite 300, Brisbane, CA 94005-1884 8 results 

						Links
						


SECYahooGoogleFinvizTradingViewStockChartsStockTwitsDownload CSV 













TC
Stat
Stk
Ins
Fil
+d
+w
+m
+q
+h
+y
avg


S%ret11210-10-24-220-14S%wins505010010010080 




Filing Date
T Date
Ticker
IssuerInc Sector
IndIndustry
Owner
oSt
Rel
Title
T
TVal
Price
L
Qty
oc
Own
H
r2y
r1y
r6m
r3m
r6w
r3w
r7d
r3d
f1d
f1w
f1m
f3m
f6m
f1y



7/25/17 18:357/21/17AIMTAimmune Therapeutics, Inc.HealthDrugPharmaceutical PreparationsBarrowcliffe Susan E.CAOGM,EuropS.dm-13422.000-6-1000D
7/25/17 18:357/21/17AIMTAimmune Therapeutics, Inc.HealthDrugPharmaceutical PreparationsBarrowcliffe Susan E.CAOGM,EuropM.dm183.02060D
7/6/17 16:057/3/17AIMTAimmune Therapeutics, Inc.HealthDrugPharmaceutical PreparationsBarrowcliffe Susan E.CAOGM,EuropM.d453.020150D
7/6/17 16:057/3/17AIMTAimmune Therapeutics, Inc.HealthDrugPharmaceutical PreparationsBarrowcliffe Susan E.CAOGM,EuropS.d-30420.260-15-1000D
11/15/16 16:0611/11/16AIMTAimmune Therapeutics, Inc.HealthDrugPharmaceutical PreparationsBarrowcliffe Susan E.CAOGM,EuropS.d-50025.005-20-1000D519010563596214-2-5-14-23
11/15/16 16:0611/11/16AIMTAimmune Therapeutics, Inc.HealthDrugPharmaceutical PreparationsBarrowcliffe Susan E.CAOGM,EuropM.d603.025200D519010563596214-2-5-14-23
11/10/16 16:0511/8/16AIMTAimmune Therapeutics, Inc.HealthDrugPharmaceutical PreparationsBarrowcliffe Susan E.CAOGM,EuropS.d-30020.003-15-1000D2373846637443145-6-24-22
11/10/16 16:0511/8/16AIMTAimmune Therapeutics, Inc.HealthDrugPharmaceutical PreparationsBarrowcliffe Susan E.CAOGM,EuropM.d453.023150D2373846637443145-6-24-22



DDerivative transaction in filing (usually option exercise)
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
AAmended filing
EError detected in filing



S - SaleSale of securities on an exchange or to another person

S - Sale+OESale of securities on an exchange or to another person (after option exercise)

F - TaxPayment of exercise price or tax liability using portion of securities received from the company

P - PurchasePurchase of securities on an exchange or from another person


Return to top
Contact
Copyright © 2017 OpenInsider.com. All rights reserved.














































Susan E.  Barrowcliffe - CEO, founder, businessman - profile

















directorpedia.net - List of CEOs, founders, board members and company directors











Susan E.  Barrowcliffe
Check out list of companies and businesses related to Susan E.  Barrowcliffe. Find out Susan E.  Barrowcliffe address and contact details. View other people related to Susan E.  Barrowcliffe - coworkers, colleagues, companions, etc.
Address:   

C/O AIMMUNE THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 300 BRISBANE 94005-1884 CA




Companies related to Susan E.  Barrowcliffe
CIKCompany NamePositionCompany Address0001631650Aimmune Therapeutics, Inc.General Manager, Europe 8000 MARINA BOULEVARD SUITE 300 BRISBANE 94005-1884




Susan E.  Barrowcliffe on the Web
Persons related to Susan E.  Barrowcliffe - Aimmune Therapeutics, Inc.NamePositionCityDANIEL C MD  ADELMANChief Medical Officer SOUTH SAN FRANCISCOSusan E.  BarrowcliffeGeneral Manager, Europe BRISBANEGregory  BeharDirector CAMBRIDGEERIC  BJERKHOLTChief Financial Officer PALO ALTOWalser  BryanSan MateoWarren L.  DeSouzaChief Financial Officer BRISBANESTEPHEN GEORGE  DILLYPresident and CEO ALAMEDARobert Myles  ElfontChief Medical Officer BRISBANEPATRICK G  ENRIGHTDirector BURLINGAMEKATHRYN E  FALBERGDirector ROCKVILLEForesite Capital Fund II, L.P.SAN FRANCISCOForesite Capital Fund III, L.P.SAN FRANCISCOForesite Capital Management II, LLC10% Owner SAN FRANCISCOForesite Capital Management III, LLCSAN FRANCISCOMark T  IwickiDirector MARLBOROUGHTananbaum  JamesSan Francisco(Anthony)  Yun  JoonkyooSan MateoJeffrey H  KnappChief Operating Officer FREMONTLongitude Capital Partners II, LLC10% Owner MENLO PARKLongitude Venture Partners II, L.P.MENLO PARKMARK  MCDADEDirector Nestle Health Science US Holdings, Inc.NORWALKSA  NESTLEVEVEY, SWITZERLANDNIMCO US, Inc.NORWALKEnright  PatrickMenlo ParkHoward V.  RaffBRISBANEMary M.  RozenmanSee Remarks BRISBANEStacey Denenberg  SeltzerDirector BRISBANEDouglas T.  SheehySee Remarks REDWOOD CITYSeltzer  StaceyNew YorkDilly, Jr.  StephenSan MateoBakker Juliet  TammenomsMENLO PARKJames B.  TananbaumSAN FRANCISCOColunga  VictorSan Mateo












 









BARROWCLIFFE SUSAN E. Top Holdings  

































WhaleWisdom









Search All
Search 13F Filers Only
Search SEC Filer
Search Stocks Only
Search Mgmt Inv. Cos Only
ETFs Only
Search Active




















                      BARROWCLIFFE SUSAN E.
                    

•   BRISBANE, CA
                      
How do I update this listing?




                                             Barrowcliffe Susan E. is based out of Brisbane.    WhaleWisdom has at least 1 insider transactions (Form 3,4,5) in our database for Barrowcliffe Susan E.. 
                                           














Summary
13D/G
Insider (Form 4)



   Create Email Alert
 




×
Email Notification.







                   ***Log In or
                   Sign-up
                   to see more advanced email alert options such as selecting any type of
                   SEC form, multiple filers or classes of filers, and much more.***
                 

                    ...or to simply have an email sent to you whenever we receive a new
                           13F filing from BARROWCLIFFE SUSAN E., enter your
                    email address below and choose 'Submit'.
                

Your email:








Cancel














Contact Info




barrowcliffe susan e.


8000 MARINA BOULEVARD, SUITE 300

BRISBANE
CA
                                                        
                                                    94005-1884


                                                      Business Phone:
                                                      (650) 614-5220
SEC SIC CODE:2834-PHARMACEUTICAL PREPARATIONS







Recent SEC Filings




4 filed on 07/25/2017
4 filed on 07/06/2017
4 filed on 02/24/2017
4 filed on 11/15/2016
4 filed on 11/10/2016
4 filed on 02/26/2016
3 filed on 01/22/2016
















Schedule 13D and 13G events since 03/31/2017

Subscription required



 
Form 4 - Non-derivative Insider Transactions Since 03/31/2017
Loading...








Elevate your investments
Try it for free

















     AIMT Company Profile & Executives - Aimmune Therapeutics Inc. - Wall Street Journal                                     DOW JONES, A NEWS CORP COMPANY         News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services.  DOW JONES  Barron's BigCharts DJX Dow Jones Newswires Factiva Financial News Mansion Global MarketWatch   Newsmart NewsPlus Private Markets Risk & Compliance WSJ.com WSJ Pro WSJ Conference WSJ Video    NEWS CORP  Big Decisions Business Spectator Checkout51 Harper Collins New York Post PropTiger REA   realtor.com Storyful The Australian The Sun The Times              DJIA ▲  21711.01 0.45%        S&P 500 ▲  2477.83 0.03%        Nasdaq ▲  6422.75 0.16%        U.S. 10 Yr ▲  14/32 yield 2.288%        Crude Oil ▲  48.72 1.73%        Euro ▲  1.1747 0.10%                 Subscribe Now Sign In      The Wall Street Journal     U.S. Edition  U.S. Asia Europe India 中国 (China) 日本 (Japan)    July 26, 2017   Today's Paper     Sections    My Journal       Home   World   U.S.   Politics   Economy   Business   Tech   Markets   Opinion   Arts   Life   Real Estate   Today's Paper   SHOW ALL SECTIONS HIDE ALL SECTIONS     World Home   Africa Asia Canada China Europe Latin America Middle East   Economy   World Video     U.S. Home   Economy Law New York Politics   Real Time Economics Washington Wire   Journal Report U.S. Video What's News Podcast     Politics Home   Washington Wire   Politics Video WSJ/NBC News Poll     Economy Home   Real Time Economics   Economic Forecasting Survey Economy Video     Business Home   Management Tech/WSJ.D   Aerospace & Defense Autos & Transportation Commercial Real Estate Consumer Products Energy Entrepreneurship Financial Services Food & Services Health Care Hospitality Law Manufacturing Media & Marketing Natural Resources Retail   CFO Journal CIO Journal CMO Today Logistics Report Risk & Compliance   Heard on the Street   Business Video Journal Report Business Podcast     Tech Home   CIO Journal   Geoffrey Fowler Christopher Mims Joanna Stern Li Yuan   Billion Dollar Startup Club Tech Video Tech Podcast Startup Stock Trader     Markets Home   Bonds Commercial Real Estate Commodities & Futures Currencies Deals Financial Services Funds Stocks Your Money   Heard on the Street MoneyBeat Wealth Adviser Ahead of the Tape   CFO Journal Journal Report Market Data Markets Video Markets Podcast MoneyBeat Podcast Watching Your Wealth Podcast     Opinion Home   James Freeman William A. Galston Daniel Henninger Holman W. Jenkins William McGurn Peggy Noonan Mary Anastasia O'Grady Jason Riley Kimberley A. Strassel   Books Film Television Theater Art Masterpiece Series Music Dance Opera Exhibition Cultural Commentary   Editorials Commentary Letters to the Editor The Weekend Interview Potomac Watch Podcast Foreign Edition Podcast Opinion Video Notable & Quotable Best of the Web Newsletter Morning Editorial Report Newsletter     Arts Home   Books Film Television Theater Art Masterpiece Series   Arts Video WSJ. Magazine     Life Home   Careers Cars Food & Drink Health Ideas Real Estate Science Sports Style & Fashion Travel   Life Video WSJ. Magazine WSJ Puzzles The Future of Everything     Real Estate Home   Commercial Real Estate House of the Day Mansion   Real Estate Video      HIDE ALL SECTIONS      Aim higher, reach further.  Get the Wall Street Journal $12 for 12 weeks. Subscribe Now   Sign In   Reveal Navigation Options    Subscribe Sign In              Aimmune Therapeutics Inc. AIMT (U.S.: Nasdaq)      search    View All companies           AT CLOSE 4:00 PM EDT 07/26/17     $21.93 USD     0.28 1.29%     Volume 228,514      AFTER HOURS 4:39 PM EDT 07/26/17    $21.93   0.00 0.00%    AFTER HOURS Vol 58,696      Volume 228,514     65 Day Avg Vol 300,716     1 Day Range 21.125 - 21.93     52 Week Range 11.66 - 27.31 (07/28/16 - 11/14/16)          1 D 5 D 1 M 3 M YTD 1 Y 3 Y    $ %            Advanced Charting Compare     Compare to Benchmark:   DJIA   S&P 500   GLOBAL DOW   NASDAQ   Health Care/Life Sciences      Compare to    Add          Open  21.70   Prior Close  21.65 (07/24/17)     1 Day    AIMT 1.29%     DJIA 0.45%     S&P Mid Cap 400 -0.85%     Health Care/Life Sciences 0.00%                             Overview Profile Key People     Overview Profile Financials Income Statement Balance Sheet Cash Flow Research & Ratings Historical Prices Options Advanced Charting              Susan E. Barrowcliffe, 58 General Manager-Europe & Senior Vice President, Aimmune Therapeutics, Inc. Ms. Susan E. Barrowcliffe is General Manager-Europe & Senior Vice President at Aimmune Therapeutics, Inc. and Head-Regulatory Affairs at APT Pharmaceuticals, Inc. Ms. Barrowcliffe was previously employed as Vice President-Regulatory Affairs by Chiron Corp., Chief Executive Officer by Pharminox Ltd, Vice President-Global Product Registration by Smithkline Beecham Plc, and Director-Drug Development by Vernalis Plc. She received her undergraduate degree from The University of Sheffield.          News Aimmune Therapeutics Inc.AIMT   Significant News Only       07/05/17 Press Release   Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy   Press Release     06/20/17 Press Release   Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress   Press Release     06/15/17 Press Release   Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017   Press Release     06/12/17 Press Release   Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy   Press Release     06/08/17 Press Release   Aimmune Therapeutics to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15(th)   Press Release     06/07/17 Press Release   Aimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of Treatment for Peanut Allergy   Press Release     05/11/17 Press Release   Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy   Press Release     05/09/17 Press Release   Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16   Press Release     05/08/17 Press Release   Aimmune Therapeutics Announces First Quarter 2017 Financial Results   Press Release     load more                All Company Executives Aimmune Therapeutics Inc.       Stephen George Dilly, 57 President, Chief Executive Officer & Director     Jeffrey H. Knapp, 51 Chief Operating Officer     Eric H. Bjerkholt, 53 Chief Financial Officer     Annette Marcantonio Vice President-Clinical Operations     Daniel C. Adelman, 59 Chief Medical Officer     Mary M. Rozenman, 36 Senior VP-Corporate Development & Strategy     Susan E. Barrowcliffe, 59 General Manager-Europe & Senior Vice President     Le-Van Nguyen Vice President-US Regulatory Affairs     Gregory Behar, 47 Director     Laura G. Hansen Vice President-Investor Relations     Kenneth F. Boehm Vice President-Human Resources     Douglas T. Sheehy, 50 Secretary & General Counsel     William Turner SVP-Global Regulatory Affairs & Quality Assurance     Mark D. McDade, 61 Chairman     Mark T. Iwicki, 50 Independent Director     Kathryn E. Falberg, 56 Independent Director     Stacey Denenberg Seltzer, 40 Independent Director     Patrick G. Enright, 55 Independent Non-Employee Director      expand          Advertisement                 Notes & Data Providers   Real-time U.S. stock quotes reflect trades reported through Nasdaq only. International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times. Quote data, except U.S. stocks, provided by SIX Financial Information. Data is provided "as is" for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.  All of the mutual fund and ETF information contained in this display was supplied by Lipper, A Thomson Reuters Company, subject to the following: Copyright  © Thomson Reuters. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Bond quotes are updated in real-time. Source: Tullett Prebon. Currency quotes are updated in real-time. Source: Tullet Prebon. Fundamental company data and analyst estimates provided by FactSet. Copyright  FactSet Research Systems Inc. All rights reserved.        Advertisement                Aimmune Therapeutics Inc: NASDAQ:AIMT quotes & news - Google FinanceCookies help us deliver our services. By using our services, you agree to our use of cookiesLearn moreGot itMy AccountSearchMapsYouTubePlayNewsGmailDriveCalendarGoogle+TranslatePhotosMoreShoppingWalletFinanceDocsBooksBloggerContactsHangoutsKeepEven more from GoogleSign inHidden fieldsSearch FinanceAdobe Flash Player is required for interactive charts. AllowFinanceAimmune Therapeutics Inc(NASDAQ:AIMT)Add to portfolioCompanySummaryNewsRelated companiesHistorical pricesFinancialsMarketsNewsPortfoliosStock screenerGoogle Domestic TrendsRecent Quotes (30 days)You have no recent quoteschg | %




Aimmune Therapeutics Inc  (Public, NASDAQ:AIMT)  
Watch this stock
 




















21.93


+0.28
(1.29%)



After Hours: 21.93
0.00
(0.00%)
Jul 26, 4:39PM EDT  
NASDAQ
real-time data -
Disclaimer

Currency in USD








Range

21.12 - 21.93



52 week

11.52 - 27.31



Open

21.70



Vol / Avg.

287,210.00/304,325.00



Mkt cap

1.09B



P/E

    -



Div/yield

    -



EPS

-2.03



Shares

50.34M



Beta

    -



Inst. own

82%





































News





Relevance



Date











All news for Aimmune Therapeutics Inc »

Subscribe






Advertisement




Events




Add AIMT to my calendars





Aug 8, 2017
Q2 2017 Aimmune Therapeutics Inc Earnings Release (Estimated)
- 4:00PM EDT -






Jun 21, 2017
Aimmune Therapeutics Inc at JMP Securities Life Science Conference



Jun 15, 2017
Aimmune Therapeutics Inc at Goldman Sachs Global Healthcare Conference



May 16, 2017
Aimmune Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference



May 8, 2017
Q1 2017 Aimmune Therapeutics Inc Earnings Release





More events from DailyFinance » 
  



Key stats and ratios




Q1 (Mar '17)
2016


Net profit margin
-
-

Operating margin
-
-

EBITD margin
-
-

Return on average assets
-36.09%
-31.62%

Return on average equity
-37.69%
-32.84%

Employees
81
-

CDP Score
-

-


Screen stocks with similar metrics »

Address
8000 Marina Blvd Ste 300BRISBANE, CA 94005-1884United States
- Map+1-650-6145220 (Phone)+1-650-6160075 (Fax)

Website links


http://www.aimmune.com/



External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters















Settings |
Technicals |



Link to this view



Volume delayed by 15 mins.Prices are not from all markets.

Sources include SIX.




















Advertisement







Related companies





Show:


Most Recent Quarter


Most Recent Annual




Add or remove columns
Save changes
Cancel







Sector: Healthcare > Industry: Specialty & Advanced Pharmaceuticals

More from FactSet »










Description




Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company's lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.


More from Reuters »








Officers and directors





Mark D. McDade

Independent Chairman of the Board





Age: 61

Bio & Compensation
 - Reuters

Stephen G. Dilly M.D. Ph.D.

President, Chief Executive Officer, Director





Age: 57

Bio & Compensation
 - Reuters

Eric H. Bjerkholt

Chief Financial Officer





Age: 57

Bio & Compensation
 - Reuters

Jeffrey H. Knapp

Chief Operating Officer





Age: 51

Bio & Compensation
 - Reuters

Susan E. Barrowcliffe

Senior Vice President, General Manager of Europe





Age: 59

Bio & Compensation
 - Reuters

Mary M. Rozenman

Senior Vice President - Strategy and Corporate Development





Age: 36

Bio & Compensation
 - Reuters

Douglas T. Sheehy J.D.

General Counsel, Secretary





Age: 50

Bio & Compensation
 - Reuters

Sue Barrowcliffe

General Manager of Europe






Bio & Compensation
 - Reuters

Daniel C. Adelman M.D.

Chief Medical Officer





Age: 56

Bio & Compensation
 - Reuters

Greg Behar

Independent Director





Age: 47

Bio & Compensation
 - Reuters



Full list on Reuters »








Google Finance Beta available in: Hong Kong - Canada - U.S. - China - U.K.Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.To see all exchange delays, please  see disclaimer.©2017 Google - Google Home - Blog - Help - Report a Problem - Privacy Policy - Terms of Service




Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft













Robot Check













Enter the characters you see below
Sorry, we just need to make sure you're not a robot. For best results, please make sure your browser is accepting cookies.










Type the characters you see in this image:








Try different image











Continue shopping











Conditions of Use




Privacy Policy


          © 1996-2014, Amazon.com, Inc. or its affiliates
          




























Amazon Prime

































Interesting Finds Updated Daily










Amazon




    Try Prime
  


















All



All Departments
Alexa Skills
Amazon Devices
Amazon Video
Amazon Warehouse Deals
Appliances
Apps & Games
Arts, Crafts & Sewing
Automotive Parts & Accessories
Baby
Beauty & Personal Care
Books
CDs & Vinyl
Cell Phones & Accessories
Clothing, Shoes & Jewelry
   Women
   Men
   Girls
   Boys
   Baby
Collectibles & Fine Art
Computers
Courses
Credit and Payment Cards
Digital Music
Electronics
Gift Cards
Grocery & Gourmet Food
Handmade
Health, Household & Baby Care
Home & Business Services
Home & Kitchen
Industrial & Scientific
Kindle Store
Luggage & Travel Gear
Luxury Beauty
Magazine Subscriptions
Movies & TV
Musical Instruments
Office Products
Patio, Lawn & Garden
Pet Supplies
Prime Exclusive
Prime Pantry
Software
Sports & Outdoors
Tools & Home Improvement
Toys & Games
Vehicles
Video Games
Wine





Go

















Departments









EN

 
      




Hello. Sign inAccount & ListsSign inAccount & ListsOrdersTry PrimeCart0






Your Amazon.comToday's DealsGift Cards & RegistrySellHelpDisability Customer Support 





















































































There's a problem loading this menu right now.
Learn more about Amazon Prime.






 Get fast, free shipping with Amazon Prime 
 Prime members enjoy FREE Two-Day Shipping and exclusive access to music, movies, TV shows, original audio series, and Kindle books. 

      >
      Get started






























 



Fast shipping and morePrime members also enjoy exclusive access to movies and TV shows, ad-free music, unlimited photo storage, and Kindle books.






Start your 30-day Prime Free Trial 

After your free trial, Amazon Prime is just $99/year.  Cancel anytime.

                    
Give the gift of Prime | 
                            Refer a friend | 
                            Have a Prime promo code?




    
    
    



Fast, FREE shipping on over 50 million eligible itemsChoose from FREE Two-Hour, Same-Day or Two-Day Delivery with Prime    
    
    



Need a last minute gift? Can’t get out of the house? Realize you forgot to pick up something? With FREE Two-Day Shipping and more from Amazon Prime, your shopping problems are solved. You get unlimited deliveries with no minimum order size, and with millions of eligible items, the options are practically limitless. When shipping to select metro areas, Prime members also get FREE Same-Day Delivery on over a million items and FREE 2-hour delivery with Prime Now on daily essentials and groceries. With FREE release-date delivery on eligible pre-order items, you can enjoy highly anticipated books, movies, and video games as soon as possible. 
Learn more about all the Prime shipping options

    
    
    



Enjoy instant access to video streaming    
    
    



Prime includes popular movies and TV shows    
    
    



Make every night a movie night with Prime Video. Your Prime membership includes instant access to thousands of movies and TV shows at no additional cost. Catch Amazon Original Series like Golden Globe-winning Transparent, Mozart in the Jungle, and Goliath, Emmy-winning Man in the High Castle, or exciting and wildly popular The Grand Tour. Stream on select Smart TVs, Roku, Xbox, Amazon Fire TV, iPhones, tablets, and Android devices. Download entertainment to your device to watch offline anywhere.
Browse movies and TV shows
    
    
    



Over two million songs. Thousands of playlists and stations.    
    
    



On-demand, ad-free music streaming     
    
    



Prime Music is a music streaming benefit featuring a growing selection of two million songs, Alexa voice-integration, and personalized recommendations at no additional cost with your Amazon Prime Membership. Unlock even more music with Amazon Music Unlimited, plus get an exclusive Prime member discount.
Learn more
    
    
    



Books, Magazines & More    
    
    



Unlimited reading on any device    
    
    



Prime Reading gives you unlimited access to over a thousand books, current issue magazines, books with Audible narration, comics, Kindle Singles, and more. With access from any device – including your phone, tablet, or Kindle – you can read however you want, whenever you want.
Learn more
    
    
    



Original audio series from Audible    
    
    



Unlimited listening to original audio series    
    
    



Get hooked on original audio series from Audible: hunt for clues with intrepid investigators, think big with bold visionaries, or ‘keep it real’ with fearless comedians. Listen to insightful and engaging playlists handcrafted for every interest and refreshed daily, drawing from news, comedy shows, articles, talks and more. Whether you want to turn rush hour into an adventure with a great story or master a new topic while riding the train, your commute will never be the same. Audible Channels–from Audible, a world leader in audio entertainment.
Learn More
    
    
    



Twitch Prime    
    
    



Get free game content every month, exclusive discounts, plus loads more    
    
    



Get a member exclusive discount on new release and preorder boxed video games. You'll get characters, vehicles, skins, and boosts for top games on Twitch, plus surprises like full indie games and exclusive loot. You also receive ad-free viewing and a free monthly Twitch channel subscription to support your favorite streamer.
Learn more
    
    
    



All your photos, together at last    
    
    



Free unlimited photo storage    
    
    



Your Prime membership comes with free unlimited photo storage through Prime Photos, which lets you securely save as many photos as you like and see them on your phone, computer, or tablet. You can share this Prime benefit and give free photo storage to up to five family members or friends. Collect photos together with your invited family and friends in the Family Vault and store memories from everyone in one safe place. New photo search technology makes it easy to find specific photos by searching for things like “sunset” or “Seattle,” and your photos are organized automatically so it’s easy to find and enjoy them.
Learn more
    
    
    



Prime Rewards    
    
    



Cardmembers earn 5% Back with a Prime Credit Card.    
    
    



Eligible Prime members can earn 5% back at Amazon.com using the Amazon Prime Rewards Visa Card or the Amazon Prime Store card. All Prime members earn 2% rewards on their debit spending with Amazon Prime Reload.
Learn More

    
    
    



Get Early Access    
    
    



30-minute early access to select Amazon Lightning Deals    
    
    



Consider yourself a techy, the best-styled fashionista on the block, or just an everyday savvy shopper? Be among the first to decide what's hot and what's not. Get 30-minute early access to select Lightning Deals on Amazon.

Shop Amazon Lightning Deals

Look for Prime eligible items, videos, music and Kindle books are clearly marked. Just look for the Prime logo when you shop. 













Back to top
Get to Know UsCareersAbout AmazonInvestor RelationsAmazon DevicesMake Money with UsSell on AmazonSell Your Services on AmazonSell on Amazon BusinessSell Your Apps on AmazonBecome an AffiliateAdvertise Your ProductsSelf-Publish with UsBecome an Amazon VendorSell Your Subscription on Amazon›See allAmazon Payment ProductsAmazon Rewards Visa Signature CardsAmazon.com Store CardAmazon.com Corporate Credit LineShop with PointsCredit Card MarketplaceReload Your BalanceAmazon Currency ConverterLet Us Help YouYour AccountYour OrdersShipping Rates & PoliciesAmazon PrimeReturns & ReplacementsManage Your Content and DevicesAmazon AssistantHelp




English



United States




Amazon Music Stream millions of songs

Amazon Drive Cloud storage from Amazon

6pm Score deals on fashion brands

AbeBooks Books, art & collectibles

ACX  Audiobook Publishing Made Easy

Alexa Actionable Analytics for the Web

Amazon Business Everything For Your Business

 

AmazonFresh Groceries & More Right To Your Door

AmazonGlobal Ship Orders Internationally

Home Services Handpicked Pros Happiness Guarantee

Amazon Inspire Digital Educational  Resources

Amazon Rapids Fun stories for  kids on the go

Amazon Restaurants Food delivery from local restaurants

Amazon Video Direct Video Distribution Made Easy

 

Amazon Web Services Scalable Cloud Computing Services

Audible Download Audio Books

AudiobookStand Discount Audiobooks on Disc

Book Depository Books With Free Delivery Worldwide

Box Office Mojo Find Movie Box Office Data

ComiXology Thousands of Digital Comics

CreateSpace Indie Print Publishing Made Easy

 

DPReview Digital Photography

East Dane Designer Men's Fashion

Fabric Sewing, Quilting & Knitting

Goodreads Book reviews & recommendations

IMDb Movies, TV & Celebrities

IMDbPro Get Info Entertainment Professionals Need

Junglee.com Shop Online in India

 

Kindle Direct Publishing Indie Digital Publishing Made Easy


Prime Now FREE 2-Hour Delivery on Everyday Items

Prime Photos Unlimited Photo Storage Free With Prime

Shopbop Designer Fashion Brands

TenMarks.com Math Activities for Kids & Schools

Warehouse Deals Open-Box Discounts

Whispercast Discover & Distribute Digital Content


 

 

Withoutabox Submit to Film Festivals

Woot! Deals and  Shenanigans

Zappos Shoes & Clothing

Souq.com Shop Online in the Middle East

Subscribe with Amazon Discover & try subscription services

 


Conditions of UsePrivacy NoticeInterest-Based Ads© 1996-2017, Amazon.com, Inc. or its affiliates










v




























Robot Check













Enter the characters you see below
Sorry, we just need to make sure you're not a robot. For best results, please make sure your browser is accepting cookies.










Type the characters you see in this image:








Try different image











Continue shopping











Conditions of Use




Privacy Policy


          © 1996-2014, Amazon.com, Inc. or its affiliates
          


















Amazon.com: Amazon Music Unlimited








































Interesting Finds Updated Daily










Amazon




    Try Prime
  


















Digital Music



All Departments
Alexa Skills
Amazon Devices
Amazon Video
Amazon Warehouse Deals
Appliances
Apps & Games
Arts, Crafts & Sewing
Automotive Parts & Accessories
Baby
Beauty & Personal Care
Books
CDs & Vinyl
Cell Phones & Accessories
Clothing, Shoes & Jewelry
   Women
   Men
   Girls
   Boys
   Baby
Collectibles & Fine Art
Computers
Courses
Credit and Payment Cards
Digital Music
Electronics
Gift Cards
Grocery & Gourmet Food
Handmade
Health, Household & Baby Care
Home & Business Services
Home & Kitchen
Industrial & Scientific
Kindle Store
Luggage & Travel Gear
Luxury Beauty
Magazine Subscriptions
Movies & TV
Musical Instruments
Office Products
Patio, Lawn & Garden
Pet Supplies
Prime Exclusive
Prime Pantry
Software
Sports & Outdoors
Tools & Home Improvement
Toys & Games
Vehicles
Video Games
Wine





Go

















Departments









EN

 
      




Hello. Sign inAccount & ListsSign inAccount & ListsOrdersTry PrimeCart0






Your Amazon.comToday's DealsGift Cards & RegistrySellHelpDisability Customer Support 






 Amazon Music Unlimited Prime Music CDs & Vinyl Download Store         Open Web Player MP3 cart Settings













































































































$7.99/mo for Prime members




Non-Prime price: $9.99/month



Change or cancel anytime




            Start your 30-day free trial
          




$7.99/mo for Prime members




Non-Prime price: $9.99/month



Change or cancel anytime




            Start your 30-day free trial
          




$7.99/mo for Prime members




Non-Prime price: $9.99/month



Change or cancel anytime




            Start your 30-day free trial
          
















Any song, anywhere




Tens of millions of songs with new releases from today's most popular artists. Listen ad-free with unlimited skips. Download for offline listening.




Any song, anywhere




Tens of millions of songs with new releases from today's most popular artists. Listen ad-free with unlimited skips. Download for offline listening.




Any song, anywhere




Tens of millions of songs with new releases from today's most popular artists. Listen ad-free with unlimited skips. Download for offline listening.
















Already using Prime Music?




Upgrade to Amazon Music Unlimited now to unlock tens of millions of songs, including the hottest new releases. Only $7.99/month or $79/year (12 months for the price of 10).




Already using Prime Music?




Upgrade to Amazon Music Unlimited now to unlock tens of millions of songs, including the hottest new releases. Only $7.99/month or $79/year (12 months for the price of 10).




Already using Prime Music?




Upgrade to Amazon Music Unlimited now to unlock tens of millions of songs, including the hottest new releases. Only $7.99/month or $79/year (12 months for the price of 10).
















Better with Echo - Just ask




Play your favorite music with innovative Alexa voice controls, exclusive to Amazon Music.




Want Amazon Music Unlimited just on your Echo? Learn More




Better with Echo - Just ask




Play your favorite music with innovative Alexa voice controls, exclusive to Amazon Music.




Want Amazon Music Unlimited just on your Echo? Learn More




Better with Echo - Just ask




Play your favorite music with innovative Alexa voice controls, exclusive to Amazon Music.




Want Amazon Music Unlimited just on your Echo? Learn More


























Choose the right Amazon Music plan for you




Learn More




Learn More




Learn More




Questions? See our FAQ.





            Start free trial
          




Choose the right Amazon Music plan for you




Learn More




Learn More




Learn More




Questions? See our FAQ.





            Start free trial
          




Choose the right Amazon Music plan for you




Learn More




Learn More




Learn More




Questions? See our FAQ.





            Start free trial
          

















There's a problem loading this menu right now.
Learn more about Amazon Prime.






 Get fast, free shipping with Amazon Prime 
 Prime members enjoy FREE Two-Day Shipping and exclusive access to music, movies, TV shows, original audio series, and Kindle books. 

      >
      Get started

















v



























Robot Check













Enter the characters you see below
Sorry, we just need to make sure you're not a robot. For best results, please make sure your browser is accepting cookies.










Type the characters you see in this image:








Try different image











Continue shopping











Conditions of Use




Privacy Policy


          © 1996-2014, Amazon.com, Inc. or its affiliates
          







